stockrow
Friday 6 November 2026
Export CDIO’s income statement to Excel — free account
Cardio Diagnostics Holdings, Inc.
CDIO Healthcare Biotechnology
Cardio Diagnostics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14,800.00, down 57.6% from fiscal 2024.
- Revenue
- +23.8%
- EPS
- +47.4%
- Free cash flow
- +2.59%
Quarter to September 2026, against a year earlier
1.65
0.03
−1.79%
Follow CDIO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | +101.4% | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | — | (1) | (5) | (8) | (8) | (6) | (6) | +79.9% | ||||||
| EBT margin, % | — | — | — | — | — | (68,933.33) | (466,100.00) | (48,987.13) | (24,021.49) | (43,906.76) | (42,429.24) | +25,026.6 pt | ||||||
| Net income | — | 0 | — | — | — | (1) | (5) | (8) | (8) | (6) | (6) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.02 | 0.01 | 0.04 | 0.04 | 0.01 | 0.00 | (22.3%) | |||||
| Earnings | — | — | — | — | — | (16.02) | (45.34) | (19.82) | (9.31) | (3.71) | (2.92) | (30.6%) | ||||||
| Cash flow | — | — | — | — | — | (15.12) | (49.52) | (13.43) | (5.57) | (3.27) | 0.00 | (31.8%) | ||||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | (1.36) | (0.24) | (0.11) | (0.06) | n/m | ||||||
| Free cash flow | — | — | — | — | — | (15.12) | (49.52) | (14.79) | (5.81) | (3.38) | 0.00 | (31.3%) | ||||||
| Book value | — | — | — | — | — | 27.60 | 41.85 | 7.00 | 10.67 | 3.98 | 0.00 | (38.4%) | ||||||
| Shares, m | — | — | — | — | — | 0 | 0 | 0 | 1 | 2 | 2 | +159.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 1,036.37 | 318.47 | 319.37 | 271.0 | ||||||
| P/B | — | — | — | — | — | 3,506.47 | 0.79 | 19.71 | 3.78 | 0.68 | 0.85 | 706.3 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 812.09 | (24.52) | 61.50 | 157.5 | ||||||
| EV/FCF | — | — | — | — | — | 0.00 | 0.14 | (9.12) | (5.44) | 0.06 | (0.16) | (2.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (5) | (6) | (5) | (6) | (6) | +76.9% | |||||
| Capex | — | — | — | — | — | 0 | 0 | (1) | 0 | 0 | 0 | +13.2% | ||||||
| Free cash flow | — | — | — | — | — | (1) | (5) | (6) | (5) | (6) | (6) | +78.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 1 | 4 | 2 | 8 | 5 | 4 | +62.1% | |||||
| Net debt | — | — | — | — | — | (1) | (4) | (1) | (8) | (5) | (4) | +77.7% | ||||||
| Shareholders’ equity | — | — | — | — | — | 1 | 4 | 3 | 10 | 7 | 6 | +59.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (112.60) | (126.80) | (156.40) | (111.20) | (70.70) | (87.24) | +41.9 pt | |||||
| ROIC | — | — | — | — | — | (69.83) | (1,543.33) | (270.31) | (302.18) | (217.55) | (227.98) | (147.7) pt | ||||||
| ROE | — | — | — | — | — | 0.00 | (173.60) | (230.77) | (133.97) | (78.62) | (93.55) | (78.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 1 | 8 | 9 | 15 | 17 | — | +103.1% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | (0.8%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026
Cardio Diagnostics Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PCSA Heatwurx Inc. | $5.1M | — (loss-making) | — | −64.29% (below 0%: shrinking) | n/m | +20.29% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SNTI Senti Biosciences, Inc. | $5.1M | — (loss-making) | — (loss-making) | −98.68% (below 0%: shrinking) | n/m | −7.48% (below 0%: shrinking) | 100.00% | (85,229.41%) | Compare |
| PULM Pulmatrix, Inc. | $5.1M | — (loss-making) | — (loss-making) | −99.86% (below 0%: shrinking) | n/m | +41.26% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CNSY Cerenome, Inc. | $5.1M | — (loss-making) | — (loss-making) | −70.43% (below 0%: shrinking) | n/m | −31.46% (below 0%: shrinking) | 100.00% | (2,203.65%) | Compare |
| IMNN Imunon, Inc. | $5.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | −4.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $5.0M | — (loss-making) | — | — | n/m | +57.80% (above 0%: growing) | — | 0.00% | Compare |
| CDIO Cardio Diagnostics Holdings, Inc. | $5.0M | — (loss-making) | — (loss-making) | +23.79% (above 0%: growing) | n/m | +2.59% (above 0%: growing) | 100.00% | (48,193.84%) | |
| CANF Can-Fite Biopharma Ltd | $4.9M | — (loss-making) | — (loss-making) | −1.18% (below 0%: shrinking) | n/m | +12.63% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NIKI Niki BioSolutions, Inc. | $4.7M | — (loss-making) | 31.9× | −32.36% (below 0%: shrinking) | +69.51% (above 0%: growing) | +58.14% (above 0%: growing) | (154.22%) | 0.00% | Compare |
| Median of peers | $5.1M | — | — | −64.29% | — | +16.46% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 5 August 2026
Ownership
Directors and executive officers, together
8.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement